Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It Is Not Only About Price!

BioDrugs - United Kingdom
doi 10.1007/s40259-019-00395-w
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Sometimes It Is Not as Much About How as It Is About Why

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2017English

C&EN Webinars - Water Purification Solutions for Analytical Labs and Why It Is Not Only About Water Needs

Chemical and Engineering News
Chemical Engineering
2014English

Prenatal Screening: It Is Not Just About Down Syndrome

BJOG: An International Journal of Obstetrics and Gynaecology
GynecologyObstetrics
2017English

It Is Not Just About Occupation, but Also About Where You Work

Community Dentistry and Oral Epidemiology
EnvironmentalPublic HealthOccupational HealthDentistry
2017English

Off-Patent Transgenic Events: Challenges and Opportunities for New Actors and Markets in Agriculture

Frontiers in Bioengineering and Biotechnology
BioengineeringBiomedical EngineeringHistologyBiotechnology
2018English

Psy145 - Impact of Biosimilar Entry on Price and Uptake of Branded Biologics for the Treatment of Autoimmune Diseases

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Is It or Is It Not a Pathogenic Mutation? Is It or Is It Not the Podocyte?

Journal of Nephropathology
Nephrology
2012English

When Is Market Incompleteness Irrelevant for the Price of Aggregate Risk (And When Is It Not)?

Journal of Economic Theory
EconomicsEconometrics
2010English

It Is Not All About BRCA: Cullin-Ring Ubiquitin Ligases in Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy